Live tape
Top 8, mentions 7d11,095NVDA4,952 mentions▲ +0.08GOOGL1,319 mentions▲ +0.03META1,172 mentions▲ +0.05NKE1,054 mentions+0.01MRVL808 mentions▲ +0.08MSFT625 mentions▲ +0.07SNDK610 mentions▲ +0.07QQQ555 mentions▲ +0.07

Equity · Healthcare

CVM

CEL-SCI Corporation · NYSE American

$1.60 +2.56% 1D Finazon · prior-day close · Aug 18, 2026
Price · Chart
Our own end-of-day closes 54 sessions
$1.75 $0.75 2 Jun 18 Aug

The line runs $1.47 on 2 June through $1.60 on 18 August, on a scale from $0.75 to $1.75. Days the market did not trade hold the previous close, flat.

The chart above plots the price of CVM over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 54 sessions over that window: $1.47 on 2 June 2026 through $1.60 on 18 August 2026.

Market cap $28.1M
Avg volume 30.3K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 31, 2026

CVM insider trades

SEC Form 4

CVM has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 4 December 2025.

Date Insider Type Shares Value
04 Dec 2025 KERSTEN GEERT R Chief Executive Officer Buy 8,389 $50K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
30 Sep 2025 TALOR EYAL Chief Scientific Officer Award 260 $2K
30 Sep 2025 KERSTEN GEERT R Chief Executive Officer Award 570 $5K
30 Sep 2025 PRICHEP PATRICIA B Chief Financial Officer Award 466 $4K
28 Jul 2025 KERSTEN GEERT R Chief Executive Officer Award 25,000 $0K
28 Jul 2025 Watson Robert Eugene Award 4,000 $0K
28 Jul 2025 PRICHEP PATRICIA B Chief Financial Officer Award 12,000 $0K
28 Jul 2025 CIPRIANO JOHN Senior Vice President Award 7,500 $0K
28 Jul 2025 TALOR EYAL Chief Scientific Officer Award 15,000 $0K
28 Jul 2025 BAILLAVOINE BRUNO JEAN-MARIE Award 4,000 $0K

CVM reported financials

SEC EDGAR XBRL

CVM reported net income of −$25.4M for the fiscal year ended 30 Sep 2025.

Figure Reported Period
Net income −$25.4M 30 Sep 2025 fiscal year
Diluted EPS −$6.27 30 Sep 2025 fiscal year
Total assets $21.4M 30 Jun 2026 at period end
Total equity $11.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CVM earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q3 2026 $-0.47
31 Mar 2026 Q2 2026 $-0.67
31 Dec 2025 Q1 2026 $-0.68
30 Sep 2025 FY 2025 $-6.27
30 Jun 2025 Q3 2025 $-1.36
31 Mar 2025 Q2 2025 $-2.33
31 Dec 2024 Q1 2025 $-3.25
30 Sep 2024 FY 2024 $-15.31

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CVM institutional holders

SEC Form 13F

2 of the 45 institutional funds we track reported a CVM position for the quarter ended 30 Jun 2026 — a combined $802K; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Renaissance Technologies Added +1,495.0% shares 572,460 $595K
Citadel Advisors New position 198,500 $206K

Source: SEC EDGAR 13F filings

CVM fails-to-deliver

SEC CNS data

On 27 Jul 2026, 1,412 shares of CVM failed to deliver (about $2K).

Settlement date Shares failed Notional % of shares out
27 Jul 2026 1,412 $2K 0.008%
21 Jul 2026 2,921 $4K 0.017%
17 Jul 2026 6,055 $7K 0.034%

Source: SEC fails-to-deliver (CNS) data